Polymyositis and dermatomyositis nursing: assessment, interventions, and NCLEX tips

Polymyositis (PM) and dermatomyositis (DM) are idiopathic inflammatory myopathies — autoimmune conditions that cause progressive proximal muscle weakness through distinct but overlapping immune-mediated mechanisms. Dermatomyositis is distinguished by characteristic skin manifestations that can precede, accompany, or even exist without clinically apparent muscle disease. Both conditions affect women more than men (2:1 ratio), with peak onset between 40 and 60 years. A juvenile form — juvenile dermatomyositis (JDM) — occurs in children and follows a somewhat different clinical course. These conditions are high-yield for NCLEX because of their distinctive skin findings, the elevated malignancy risk associated with DM, and the complex pharmacology that demands careful nursing monitoring. They sit within a broader spectrum of inflammatory myopathies that also includes rheumatoid arthritis overlap myositis and conditions such as scleroderma with myopathic features.

PM vs DM: quick reference

Pathophysiology

The two conditions share a downstream phenotype of proximal muscle weakness but arrive there through different immune mechanisms — a distinction that matters for both biopsy interpretation and targeted treatment.

In polymyositis, cytotoxic CD8+ T-cells are the primary effectors. These cells invade individual muscle fibers directly at the endomysial level, triggering necrosis and inflammation. This pattern — CD8+ T-cells attacking muscle fibers from within the fascicle — is the histologic hallmark that distinguishes PM from DM on biopsy.

In dermatomyositis, the primary lesion is complement-mediated microangiopathy. Complement activation damages small blood vessels in the perimysial and perivascular compartments, leading to endothelial swelling, capillary dropout, muscle ischemia, and subsequent perifascicular atrophy — the thinning of muscle fibers at the edge of fascicles that is pathognomonic for DM. Skin involvement follows the same vascular mechanism, explaining why the rashes track sun-exposed vasculature-rich areas.

Interstitial lung disease (ILD) complicates up to 40% of cases across both PM and DM. The mechanisms overlap with those driving muscle injury but extend to pulmonary interstitium, particularly in patients carrying antisynthetase antibodies such as anti-Jo-1 or the high-risk anti-MDA5 antibody.

Clinical presentation

Muscle findings (both PM and DM)

Proximal symmetric muscle weakness is the cardinal feature. The shoulder girdle and hip girdle are affected earliest and most severely — leading to the functional limitations that patients typically present with:

• Difficulty raising arms above shoulder height (e.g., reaching for shelves, washing hair)
• Inability to rise from a chair without using the arms for push-off
• Difficulty climbing stairs or stepping up from low surfaces
• Neck flexor weakness causing inability to lift the head from a pillow — an often-underappreciated sign that nurses should assess specifically
• Pharyngeal muscle involvement producing dysphagia, which carries significant aspiration risk — covered further in the nursing interventions section

Distal muscle strength is preserved early in the disease course. This is an important NCLEX discriminator: distal weakness points toward peripheral neuropathy, not inflammatory myopathy. Arthralgia or frank arthritis occurs in approximately 30% of patients.

The weakness of PM and DM shares features with myasthenia gravis — both cause proximal weakness and dysphagia — but can be differentiated by the absence of fatigability with repetitive activity in myopathy, the markedly elevated CPK in PM/DM, and characteristic EMG and biopsy findings.

Skin findings (DM only)

The skin manifestations of dermatomyositis are among the most clinically recognizable in all of rheumatology. Two findings are considered pathognomonic — meaning their presence alone is sufficient to make a clinical diagnosis even without biopsy.

Gottron’s papules are violaceous (violet-red) flat-topped papules occurring over the dorsal aspect of the metacarpophalangeal (MCP) and interphalangeal (IP) joints of the hands. They have a slightly scaly or lichenoid surface. Their location — over the knuckles on the back of the hand — distinguishes them from the knuckle pads of other conditions and from lupus, which spares the knuckles. On NCLEX, remember: Gottron’s papules are on the knuckle skin, not the palms.

Heliotrope rash is a violaceous discoloration of the upper eyelids, often accompanied by periorbital edema. The term derives from the color of the heliotrope flower. In dark-skinned patients it may appear as periorbital swelling rather than obvious color change. The heliotrope rash is bilateral and affects the upper lids — this distinguishes it from the malar butterfly rash of lupus, which involves the cheeks and spares the eyelids.

Additional DM skin manifestations include:

• V-sign — erythema in a V-shaped distribution over the anterior chest and neck, tracking the sun-exposed décolletage area
• Shawl sign — erythema over the posterior shoulders, upper back, and posterior neck, following the distribution of a shawl
• Mechanic’s hands — hyperkeratosis, cracking, and fissuring of the lateral fingers and palmar surfaces, resembling the hands of someone doing manual labor; most strongly associated with antisynthetase syndrome (see below)

Amyopathic dermatomyositis is a subtype in which patients have the full spectrum of DM skin manifestations without clinically or biochemically apparent muscle weakness. This is not a benign variant — amyopathic DM still carries elevated malignancy risk and, particularly in anti-MDA5-positive patients, carries the highest risk of rapidly progressive ILD. Nurses should not assume that skin-only disease means low-risk disease.

Antisynthetase syndrome

Antisynthetase syndrome is an overlap syndrome occurring in both PM and DM, defined by the presence of antibodies against aminoacyl-tRNA synthetase enzymes — most commonly anti-Jo-1 (anti-histidyl-tRNA synthetase), which accounts for the majority of antisynthetase-positive cases. The clinical triad is:

1. Interstitial lung disease — often the most serious manifestation; may precede muscle disease
2. Inflammatory arthritis — typically non-erosive, affecting the small joints
3. Mechanic’s hands — the hyperkeratotic cracked hand changes described above

Additional features frequently seen in antisynthetase syndrome include fever, Raynaud’s phenomenon, and constitutional symptoms. Patients with anti-Jo-1 tend to respond to immunosuppression better than those with anti-MDA5, though ILD still worsens prognosis across all antisynthetase-positive patients.

Antibody reference

Diagnostic workup

Laboratory studies: CPK is the primary marker of active muscle injury and can be markedly elevated — up to 50 times the upper limit of normal in active PM. Aldolase, LDH, AST, and ALT are also elevated due to muscle necrosis. ESR and CRP are elevated as general inflammatory markers. ANA is positive in approximately 50% of patients (lower specificity than in lupus). Myositis-specific antibody panel (anti-Jo-1, anti-Mi-2, anti-MDA5, anti-SRP, anti-TIF1-γ) provides prognostic and phenotypic information. CBC and comprehensive metabolic panel are performed as baseline.

EMG: Shows a myopathic pattern — short-duration, low-amplitude, polyphasic motor unit potentials (MUPs). This is the inverse of the neuropathic pattern (long-duration, high-amplitude MUPs), making EMG a useful tool for distinguishing myopathy from neuropathy when the clinical picture is unclear.

MRI: Demonstrates muscle edema and signal changes (T2 hyperintensity) in affected muscle groups. MRI is increasingly used to guide biopsy site selection — targeting the most actively inflamed muscle improves diagnostic yield without having to sample clinically weakest areas that may show only end-stage fibrosis.

Muscle biopsy: The definitive diagnostic tool. PM shows CD8+ T-cell endomysial infiltration invading individual muscle fibers. DM shows CD4+ T-cell and B-cell perimysial and perivascular inflammation, with perifascicular atrophy on cross-section. Biopsy findings also exclude inclusion body myositis and necrotizing autoimmune myopathy, which require different management.

Skin biopsy (DM): Can confirm DM diagnosis when skin findings are present, showing interface dermatitis and mucin deposition. Less invasive than muscle biopsy.

Cancer screening for DM: All newly diagnosed DM patients require malignancy screening given the 3–5 times elevated risk. Standard workup includes CT of the chest, abdomen, and pelvis; pelvic ultrasound in women; age-appropriate cancer screening (mammography, colonoscopy). Screening is repeated annually for at least 3 years after DM diagnosis. Anti-TIF1-γ positivity should prompt the most thorough cancer search.

Pulmonary function tests (PFTs): Baseline spirometry and diffusing capacity for carbon monoxide (DLCO) at diagnosis, with serial monitoring for ILD detection and progression. Declining FVC or DLCO on serial testing indicates ILD progression and should prompt treatment escalation.

Medical management

Treatment follows a step-up approach from corticosteroids through steroid-sparing agents to biologic therapy for refractory cases. Understanding the indications, mechanisms, and monitoring requirements for each agent is essential for NCLEX pharmacology and for safe clinical practice.

1. Corticosteroids (prednisone) First-line induction therapy at 1 mg/kg/day, typically 60–80 mg/day in adults. Response is monitored by serial CPK measurements and functional strength assessment. Once CPK normalizes and strength improves, prednisone is tapered slowly — typically over months. Nurses must recognize steroid myopathy as a paradoxical complication: during taper, patients may develop new proximal weakness that mimics disease flare. The distinguishing feature is that CPK remains normal in steroid myopathy (muscle is structurally intact but physiologically impaired), whereas a true disease flare causes CPK elevation. Escalating the steroid dose in steroid myopathy worsens the problem rather than helping.

2. Methotrexate The most commonly used steroid-sparing agent. Administered weekly (not daily — a frequent source of medication errors). Folic acid 1 mg daily is co-prescribed to reduce mucositis and hepatotoxicity. Monthly LFTs during initiation; CBC monitoring. Teratogenic — effective contraception required. Methotrexate is contraindicated in patients with significant ILD because of its own pulmonary toxicity risk, which can be difficult to distinguish from disease-related ILD progression. For ILD-predominant disease, mycophenolate is preferred.

3. Azathioprine Steroid-sparing alternative when methotrexate is contraindicated (including ILD, hepatic disease, renal impairment). Thiopurine methyltransferase (TPMT) enzyme activity must be checked before starting — TPMT deficiency leads to accumulation of thiopurine metabolites and severe life-threatening myelosuppression. Slow onset of action (3–6 months). LFTs and CBC monitoring ongoing. For the full immunosuppression pharmacology framework, see the dedicated reference.

4. Mycophenolate mofetil Preferred steroid-sparing agent for ILD-predominant PM/DM. Better pulmonary safety profile than methotrexate. Teratogenic — Category D, requires effective contraception. GI side effects (nausea, diarrhea) common. CBC monitoring for cytopenias.

5. IVIG (intravenous immunoglobulin) Used for refractory disease and as bridge therapy in acute severe situations, particularly acute severe dysphagia with aspiration risk. Monthly infusions. Before administering IVIG, screen for IgA deficiency — patients with IgA deficiency who receive IVIG products containing IgA can develop anaphylaxis due to anti-IgA antibodies. Monitor renal function (IVIG can cause osmotic nephropathy), and watch for infusion reactions including headache, chills, and blood pressure changes.

6. Rituximab Anti-CD20 monoclonal antibody targeting B-cells. Used for refractory PM/DM that has failed conventional therapy. Clinical trial data (RIM trial) showed benefit strongest in anti-Jo-1 and anti-Mi-2 positive patients. Progressive multifocal leukoencephalopathy (PML) is a rare but serious risk — screen all patients for JC virus antibody status before initiation. Screen for hepatitis B reactivation before and during treatment. Infusion reactions are common with the first dose.

Pharmacotherapy reference

Nursing assessment and interventions

Musculoskeletal and functional assessment

Proximal muscle weakness assessment should be systematic and functional:

• Shoulder girdle: Can the patient raise both arms above the head independently? Can they lift against resistance?
• Hip girdle: Can the patient rise from a standard chair without using the arms for leverage? This is one of the most reliable bedside tests for proximal hip girdle weakness.
• Stairs: Can the patient ascend a standard step without pulling on a rail?
• Neck flexors: Can the patient lift the head off the pillow while supine? Neck flexor weakness is disproportionately common in PM/DM and is often missed in routine assessment.

Fall risk is elevated due to proximal hip weakness, which impairs balance during transitions and ambulation. Institute fall precautions: bed rails, non-slip footwear, call light within reach. Physical therapy (PT) referral is essential — PT will assess function, provide assistive devices, and design an appropriate exercise program. During active disease, high-intensity resistance exercise can worsen inflammation; progressive resistance training is appropriate in remission.

Occupational therapy can assist with ADL modifications — adaptive equipment for dressing, grooming, and kitchen tasks reduces injury risk and preserves independence during the period of maximal weakness.

Dysphagia and aspiration management

Pharyngeal muscle weakness is one of the most dangerous complications of PM/DM, carrying a high risk of aspiration pneumonia. Nursing assessment and intervention are critical:

• Assess swallowing at every meal — watch for coughing or choking, wet/gurgly voice quality, food pocketing, or patient-reported difficulty
• Refer to speech-language pathology (SLP) for formal swallowing evaluation, including modified barium swallow study if indicated
• Maintain HOB elevated at 30–45° during and after all meals and oral medication administration
• Implement and document aspiration precautions in the care plan
• If SLP recommends diet modification, ensure the correct texture/consistency is ordered and communicated to the dietary team and all nursing staff
• Small, frequent meals reduce the effort required per eating episode
• Soft or pureed diet if dysphagia is clinically significant; thickened liquids per SLP recommendation
• If dysphagia is severe and aspiration risk is high, discuss enteral nutrition with the medical team

Respiratory monitoring

ILD is the leading cause of mortality in PM/DM. Active nursing monitoring is warranted:

• Assess respiratory rate, depth, and effort at each shift
• Monitor oxygen saturation — trending decline is as important as single values
• Report new or worsening dyspnea on exertion, dry cough, or declining SpO2 to the provider
• Anti-MDA5-positive patients are at highest risk for rapidly progressive ILD — oxygen saturation can deteriorate quickly and may warrant more frequent monitoring
• Baseline and serial PFT results should be noted in the care plan; declining FVC below 50% predicted or rapidly falling DLCO signals high risk
• Encourage smoking cessation — smoking accelerates ILD progression and worsens respiratory reserve in all inflammatory myopathy patients

Skin care (DM)

The skin manifestations of DM are not merely cosmetic — they reflect active immune-mediated inflammation and require targeted nursing care:

• Assess Gottron’s papules, heliotrope rash, V-sign, and shawl sign at each visit, noting distribution and any change in extent or severity
• Photoprotection is a clinical intervention, not optional lifestyle advice: UV exposure directly worsens DM skin disease and may trigger flares. Educate patients to apply broad-spectrum SPF 50+ sunscreen daily (even on cloudy days), wear sun-protective clothing (long sleeves, wide-brimmed hat), and avoid peak sun hours
• Apply emollients to mechanic’s hands to prevent cracking and secondary infection
• Avoid skin trauma — even minor friction can cause Koebner phenomenon in DM
• Assess for skin breakdown, particularly over bony prominences in patients with reduced mobility; see the pressure injury prevention reference for full staging and prevention protocol
• For inpatients, document skin status at admission and reassess at each shift

Immunosuppression education

All patients on immunosuppressive therapy require targeted education that should be documented and reinforced at each encounter:

• Infection recognition: Any fever above 100.4°F (38°C) requires prompt medical evaluation — do not wait to see if it resolves. Common infections can progress rapidly in immunosuppressed patients.
• Vaccine safety: No live vaccines while on immunosuppression (includes MMR, varicella, live influenza, yellow fever). Killed/inactivated vaccines are safe. Pneumococcal and annual inactivated influenza vaccines are recommended.
• Medication adherence: Prednisone must never be stopped abruptly — abrupt discontinuation risks adrenal crisis; carry a medical alert ID indicating steroid use.
• Methotrexate specifics: Stress weekly (not daily) dosing; folic acid daily; avoid alcohol; report mouth sores, significant nausea, or shortness of breath immediately.
• Sun protection for DM: Already covered above — reinforce that this is disease management, not cosmetic preference.

Psychosocial support

Chronic inflammatory myopathy creates substantial psychosocial burden: fatigue, visible skin changes, functional loss, and the unpredictability of relapse. Screen for depression and anxiety at each visit using a validated tool. Fatigue in PM/DM is multifactorial (active inflammation, deconditioning, medication effects, poor sleep) and often underestimated by clinicians. Normalize its severity and address it in the care plan. Connect patients with myositis support networks and patient advocacy organizations — peer support has documented benefit in chronic rheumatic disease management.

Complications

Interstitial lung disease (ILD) is the most significant source of morbidity and mortality in PM/DM. It occurs in up to 40% of patients. Anti-MDA5-positive amyopathic DM carries the highest risk of rapidly progressive ILD, which can be fatal within weeks of presentation if not treated aggressively. Anti-Jo-1 patients develop ILD at high rates but tend to respond better to immunosuppression.

Aspiration pneumonia results from pharyngeal muscle weakness and dysphagia, and represents a preventable cause of morbidity in hospitalized patients. Consistent aspiration precautions, SLP involvement, and positioning protocols are the primary nursing interventions. See the pneumonia nursing reference for full management.

Cardiac involvement is most pronounced in anti-SRP-positive PM. Manifestations include arrhythmias (heart block, ventricular arrhythmias), conduction abnormalities, and cardiomyopathy. Baseline ECG and echocardiogram are recommended in all newly diagnosed patients, with monitoring determined by initial findings and ongoing symptoms.

Malignancy is an important complication specifically associated with DM, which carries a 3–5 times elevated risk of underlying malignancy compared with the general population. The most commonly associated cancers are ovarian, lung, gastrointestinal, and nasopharyngeal. Anti-TIF1-γ positivity confers the highest cancer risk. Screening is mandatory at DM diagnosis and annually for at least 3 years.

Steroid myopathy is a paradoxical complication of the primary treatment. During prednisone tapering, new proximal weakness can emerge that is not due to disease flare but to corticosteroid-induced muscle damage. The key distinguishing feature: CPK remains normal in steroid myopathy, whereas a true PM/DM flare elevates CPK. Escalating steroids in steroid myopathy worsens the problem. Management is to reduce or hold the steroid taper and allow time for recovery.

Calcinosis — subcutaneous or intramuscular calcium deposits — is more common in juvenile dermatomyositis than adult PM/DM but can occur in adults, particularly with longstanding disease. Calcium nodules are painful, can ulcerate through the skin, and are prone to secondary infection. No consistently effective medical treatment exists, though early aggressive immunosuppression in JDM is thought to reduce calcinosis risk. Wound care for ulcerated calcinosis lesions follows standard pressure injury and wound management principles.

Contractures and deconditioning occur as consequences of prolonged severe weakness and immobility. Physical and occupational therapy early in the disease course help minimize these secondary complications.

NCLEX tips

These points represent the highest-yield exam content for polymyositis and dermatomyositis:

• PM = no skin findings; DM = skin + muscle (or skin only = amyopathic DM). No skin involvement in a patient with proximal muscle weakness points toward PM, not DM. Do not add skin findings to a PM question stem.

• Gottron’s papules are on the dorsal MCP/IP joints — not the palms. Heliotrope rash is periorbital (upper eyelids) — not malar. The malar butterfly rash of lupus spares the eyelids; heliotrope spares the cheeks. These are frequently reversed in wrong-answer options.

• Proximal weakness = myopathy; distal weakness = peripheral neuropathy. PM and DM never cause isolated distal weakness early in the disease course. An answer option describing foot drop or finger weakness points away from inflammatory myopathy.

• Elevated CPK = active muscle disease; normal CPK during steroid taper + new weakness = steroid myopathy. The therapeutic decision diverges: active disease flare requires increasing immunosuppression; steroid myopathy requires reducing or pausing the steroid taper. CPK is the differentiating lab.

• Any new diagnosis of DM → mandatory cancer screening at diagnosis and annually for 3 years. Anti-TIF1-γ positivity = highest cancer risk. CT chest/abdomen/pelvis plus pelvic ultrasound (women) is standard.

• Anti-MDA5 + amyopathic DM = highest ILD risk with potential for rapid deterioration. This patient requires close respiratory monitoring even if muscle weakness is absent or mild. Do not be falsely reassured by intact strength.

• Anti-Jo-1 = antisynthetase syndrome: ILD + inflammatory arthritis + mechanic’s hands. Mechanic’s hands (hyperkeratotic, cracked lateral fingers) in a patient with proximal weakness and dyspnea should trigger antisynthetase syndrome as the first consideration.

• Methotrexate is contraindicated in significant ILD due to its own pulmonary toxicity risk. In ILD-predominant PM/DM, mycophenolate mofetil is the preferred steroid-sparing agent.

• Before giving IVIG, check IgA level. IgA-deficient patients who receive IgA-containing IVIG products can develop anaphylaxis from pre-formed anti-IgA antibodies. This check must occur before the first infusion.

• Aspiration precautions for dysphagia: HOB elevated 30–45° during and after meals, SLP referral, thickened liquids per SLP recommendation, document in care plan. Pharyngeal weakness + lying flat = aspiration risk.

• Photoprotection in DM is a clinical intervention. UV exposure directly worsens skin disease. SPF 50+ sunscreen daily, sun-protective clothing, and avoiding peak sun hours are disease-management recommendations, not optional lifestyle advice.

• Azathioprine: check TPMT enzyme activity before starting. TPMT deficiency causes accumulation of cytotoxic thiopurine metabolites → severe bone marrow suppression. This pharmacogenomic check is mandatory and is a frequently tested NCLEX nursing consideration.

The inflammatory myopathies connect to the broader rheumatoid arthritis and connective tissue disease cluster. For related autoimmune conditions, see the lupus nursing, scleroderma nursing, and Sjogren’s syndrome nursing references. For immunosuppression pharmacology across the full rheumatology formulary, see the immunosuppression pharmacology nursing reference.